EARLY STAGE HER2+ BREAST CANCER
Clinical trials for EARLY STAGE HER2+ BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new EARLY STAGE HER2+ BREAST CANCER trials appear
Sign up with your email to follow new studies for EARLY STAGE HER2+ BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could 6 months of therapy be enough for some breast cancer patients?
Disease control Recruiting nowThis phase 3 trial is testing whether 6 months of HER2-targeted therapy (trastuzumab and pertuzumab) works as well as the standard 12 months for people with early-stage HER2+ breast cancer who had a complete response to initial chemotherapy. About 1,500 participants will be rando…
Matched conditions: EARLY STAGE HER2+ BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 20:00 UTC
-
Travel time may impact breast cancer treatment completion
Knowledge-focused Recruiting nowThis study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…
Matched conditions: EARLY STAGE HER2+ BREAST CANCER
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gene test may guide breast cancer treatment decisions
Knowledge-focused Recruiting nowThis study is testing whether a genetic test called HER2DX can help doctors decide on the best treatment for people with early-stage HER2-positive breast cancer. The study will enroll 60 patients and observe how often the test results change the treatment plan recommended by a te…
Matched conditions: EARLY STAGE HER2+ BREAST CANCER
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC